These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

279 related items for PubMed ID: 2683796

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Development of capture assays for different modifications of human low-density lipoprotein.
    Virella G, Derrick MB, Pate V, Chassereau C, Thorpe SR, Lopes-Virella MF.
    Clin Diagn Lab Immunol; 2005 Jan; 12(1):68-75. PubMed ID: 15642987
    [Abstract] [Full Text] [Related]

  • 29. Low density lipoprotein undergoes oxidative modification in vivo.
    Palinski W, Rosenfeld ME, Ylä-Herttuala S, Gurtner GC, Socher SS, Butler SW, Parthasarathy S, Carew TE, Steinberg D, Witztum JL.
    Proc Natl Acad Sci U S A; 1989 Feb; 86(4):1372-6. PubMed ID: 2465552
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Antioxidants suppress plasma levels of lectinlike oxidized low-density lipoprotein receptor-ligands and reduce atherosclerosis in watanabe heritable hyperlipidemic rabbits.
    Oka K, Yasuhara M, Suzumura K, Tanaka K, Sawamura T.
    J Cardiovasc Pharmacol; 2006 Oct; 48(4):177-83. PubMed ID: 17086097
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Presence of autoantibodies against oxidatively modified low-density lipoprotein in essential hypertension: a biochemical signature of an enhanced in vivo low-density lipoprotein oxidation.
    Maggi E, Marchesi E, Ravetta V, Martignoni A, Finardi G, Bellomo G.
    J Hypertens; 1995 Jan; 13(1):129-38. PubMed ID: 7759843
    [Abstract] [Full Text] [Related]

  • 36. Immunization of low density lipoprotein (LDL) receptor-deficient rabbits with homologous malondialdehyde-modified LDL reduces atherogenesis.
    Palinski W, Miller E, Witztum JL.
    Proc Natl Acad Sci U S A; 1995 Jan 31; 92(3):821-5. PubMed ID: 7846059
    [Abstract] [Full Text] [Related]

  • 37. In vivo inhibition of foam cell development by probucol in Watanabe rabbits.
    Steinberg D, Parthasarathy S, Carew TE.
    Am J Cardiol; 1988 Jul 25; 62(3):6B-12B. PubMed ID: 3394654
    [Abstract] [Full Text] [Related]

  • 38. Immunogenicity of malondialdehyde-modified low density lipoproteins. Studies with monoclonal antibodies.
    Gonen B, Fallon JJ, Baker SA.
    Atherosclerosis; 1987 Jun 25; 65(3):265-72. PubMed ID: 2441716
    [Abstract] [Full Text] [Related]

  • 39. Autoantibodies against oxidatively-modified LDL in uremic patients undergoing dialysis.
    Maggi E, Bellazzi R, Gazo A, Seccia M, Bellomo G.
    Kidney Int; 1994 Sep 25; 46(3):869-76. PubMed ID: 7996809
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.